Sygnis Pharma neurology news

Sygnis will restructure and reduce headcount by 19 (37%) to 32 to save cash. Sygnis said it will focus on AX200, an endogenous granulocyte colony-stimulating factor (G-CSF) protein, which is in a Phase II trial to treat stroke, with data expected by mid-2011. Sygnis said its core preclinical and clinical development teams will stay intact to complete their ongoing work. Further terms were not disclosed. ...